Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_center" colspan="2">Characteristics</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Age (years)</td><td class="align_center">58.2 ± 7.5</td></tr><tr><td class="align_left">Female/total (<i>n</i>, %)</td><td class="align_center">9/21 (42.9)</td></tr><tr><td class="align_left">Duration of diabetes mellitus (years)</td><td class="align_center">11.6 ± 5.6</td></tr><tr><td class="align_left">HbA1c (mg/dl)</td><td class="align_center">6.5 ± 1.0</td></tr><tr><td class="align_left">PRP treated (<i>n</i>, %)</td><td class="align_center">5 (23.8)</td></tr><tr><td class="align_left" colspan="2"><hr/></td></tr><tr><td class="align_left" colspan="2"><i>Prior anti-VEGF injections (n, %)</i></td></tr><tr><td class="align_left"> Ranibizumab</td><td class="align_center">24 (38.1)</td></tr><tr><td class="align_left"> Conbercept</td><td class="align_center">33 (52.4)</td></tr><tr><td class="align_left"> Aflibercept</td><td class="align_center">6 (9.5)</td></tr><tr><td class="align_left">BCVA (logMAR)</td><td class="align_center">0.65 ± 0.21</td></tr><tr><td class="align_left">IOP (mmHg)</td><td class="align_center">14.4 ± 3.04</td></tr><tr><td class="align_left">CST (<i>μ</i>m)</td><td class="align_center">453.4 ± 68.7</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Patient clinical characteristics (<i>n</i> = 21).</div>

Journal of Ophthalmology

tab1

Table 1

Table 1: Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema 